Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a group of drugs used ... For example, research has shown that treatment with Ozempic, Trulicity, Rybelsus, or Victoza is linked to ...

2 GLP-1 receptor agonists mimic the body’s production of GLP-1 and are approved to treat patients with obesity and type 2 diabetes. 1 GLP-1 receptor agonists activate the GLP-1 receptors located ...

There is also a similar medication called tirzepatide (Mounjaro/Zepbound), which is a dual GLP-1/GIP receptor agonist. This means it works on GLP-1, as well as another receptor called glucose ...

Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for ...

In older adults with diabetes, GLP-1 receptor agonists ... molecular structure of GLP-1 agonist agent (semaglutide [Ozempic], ...

Seven different GLP-1 receptor agonists were investigated among the trials, including semaglutide (also known as Ozempic or Wegovy), dulaglutide (Trulicity) and liraglutide (Victoza). The results ...

For people trying to quit smoking, use of a GLP-1 receptor agonist may help prevent weight gain, a common barrier to quitting, researchers said here. In a systematic review and meta-analysis of three ...

GLP-1 receptor agonists may aid smoking cessation by curbing cravings and mitigating weight gain, which often are impediments ...

GLP-1 receptor agonists, commonly used for type 2 diabetes and obesity, significantly reduce post-cessation weight gain in individuals quitting smoking, with users losing weight compared to controls.

GLP-1 receptor agonists promote the feeling of fullness before eating via neurons in the dorsomedial hypothalamus, according to a new study. The findings offer new insights into the neural ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes ...

Older adults with type 2 diabetes newly treated with a GLP-1 receptor agonist had a lower risk for depression than DPP-4 inhibitor users. There was no difference for depression risk between new ...